3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 4
1
Phase 3
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Specimen Handling
273
Magnetic Resonance Spectroscopy
224
pembrolizumab
214
Carboplatin
173
Biopsy
166
Cisplatin
159
Nivolumab
149
Cyclophosphamide
133
Radiotherapy
117
Paclitaxel
117
Gemcitabine
112
Bevacizumab
92
durvalumab
86
Dexamethasone
80
Rituximab
76
Oxaliplatin
73
atezolizumab
68
Capecitabine
67
venetoclax
66
Fluorouracil
66
Doxorubicin
65
Docetaxel
65
Etoposide
63
Radiosurgery
60
Radiation
57
Prednisone
57
Cytarabine
56
Ipilimumab
55
Pemetrexed
54
Taxes
52
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
bosutinib
×
90 days
×
Clear all
NCT04626024
2026-05-04
TOKIN
Baylor College of Medicine
Phase 2
Active not recruiting
17 enrolled
NCT03297606
2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2
Recruiting
720 enrolled